"Kv1.1 Potassium Channel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A delayed rectifier subtype of shaker potassium channels that is commonly mutated in human episodic ATAXIA and MYOKYMIA.
| Descriptor ID |
D051662
|
| MeSH Number(s) |
D12.776.157.530.400.600.900.500.124 D12.776.543.550.450.750.900.124.311 D12.776.543.550.450.750.900.500.124 D12.776.543.585.400.750.900.624.124
|
| Concept/Terms |
Kv1.1 Potassium Channel- Kv1.1 Potassium Channel
- Potassium Channel, Kv1.1
- KCNA1 Potassium Channel
- Potassium Channel, KCNA1
|
Below are MeSH descriptors whose meaning is more general than "Kv1.1 Potassium Channel".
Below are MeSH descriptors whose meaning is more specific than "Kv1.1 Potassium Channel".
This graph shows the total number of publications written about "Kv1.1 Potassium Channel" by people in this website by year, and whether "Kv1.1 Potassium Channel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 5 | 5 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Kv1.1 Potassium Channel" by people in Profiles.
-
KCNA1 gain-of-function epileptic encephalopathy treated with 4-aminopyridine. Ann Clin Transl Neurol. 2023 04; 10(4):656-663.
-
Loss of functional System x-c uncouples aberrant postnatal neurogenesis from epileptogenesis in the hippocampus of Kcna1-KO mice. Cell Rep. 2022 11 22; 41(8):111696.
-
Expression and function of Kv1.1 potassium channels in human atria from patients with atrial fibrillation. Basic Res Cardiol. 2015 Sep; 110(5):505.
-
Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Mar Drugs. 2015 Jan 16; 13(1):529-42.
-
A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep. 2014 Mar 28; 4:4509.
-
A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 2012 Nov 16; 586(22):3996-4001.
-
Oxidation of NADPH on Kvbeta1 inhibits ball-and-chain type inactivation by restraining the chain. Proc Natl Acad Sci U S A. 2011 Apr 05; 108(14):5885-90.
-
Kv1.1/1.2 channels are downstream effectors of nitric oxide on synaptic GABA release to preautonomic neurons in the paraventricular nucleus. Neuroscience. 2007 Oct 26; 149(2):315-27.
-
Mu opioid receptor activation inhibits GABAergic inputs to basolateral amygdala neurons through Kv1.1/1.2 channels. J Neurophysiol. 2006 Apr; 95(4):2032-41.
-
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.